Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04035811 · ClinicalTrials.gov registry record
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
A clinical trial of Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
- Active
- Registry status
- 271
- Enrollment target
- 20
- Study locations
NCT04035811: Active study of Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
NCT04035811 is a study of Achondroplasia that is active but no longer recruiting, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 271 participants, above the 121-participant average among 9 other Achondroplasia trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04035811, a study of Achondroplasia, is active but no longer recruiting, sponsored by QED Therapeutics, a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- 271 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. No study medication will be administered.
Conditions Studied
Study Locations (20)
Other
- Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan - Buenos Aires
- Murdoch Children's Research Institute - Parkville
- Hopital Femme Mere Enfant - Lyon
- Hopital Necker-Enfants Malades - Paris
- Hopital des Enfants - Toulouse
- Otto-von-Guericke-University Magdeburg Medical Fakulty - Magdeburg
- Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlino - Milan
- Rare Disease Unit Fondazione Policlinico A Gemelli IRCCS - Rome
Ontario
- Children's Hospital - London Health Sciences Center - London
- University of Ottawa - Ottawa
California
- Benioff Children's Hospital Oakland - Oakland
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Nemours Alfred I. Dupont Hospital for Children - Wilmington
Maryland
- Johns Hopkins School of Medicine - Baltimore
Missouri
- University of Missouri - Columbia
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2026-06 |
What the registry record for NCT04035811 still lists
NCT04035811 is an observational study that tracks outcomes without assigning an intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, above the 121-participant average among 9 other Achondroplasia trials with a reported enrollment target (124% higher).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT04035811 names 20 study sites across 12 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT04035811 about?
NCT04035811 is a clinical study titled "Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)". This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments ...
What is the current status of trial NCT04035811?
This trial is currently active not recruiting. The enrollment target is 271 participants. The study started on 2019-08-12. Estimated completion is 2026-06.
What conditions does trial NCT04035811 study?
This clinical trial studies the following conditions: Achondroplasia.
Who is sponsoring clinical trial NCT04035811?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04035811 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04035811's enrollment target sits among peer trials
271 2nd of 9 the highest of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI